Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancer
Lung cancer is a highly prevalent type of cancer, accounting for 11.6% of all cancer incidences. Early detection and treatment can significantly improve the survival rate and quality of life of patients; however, there is no accurate, effective, and easy-to-use test for early lung cancer screening....
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Medical Technology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmedt.2022.982308/full |
| _version_ | 1811210757567676416 |
|---|---|
| author | Zhen Sun Peng Li Zhaojun Wu Bin Li Wenjing Li Mingming Zhao Xiaobin Zhou Zeyao Wang Zhongjie Yu Wenna Liu Wenshu Zhu Haibo Wang Yongjie Wang |
| author_facet | Zhen Sun Peng Li Zhaojun Wu Bin Li Wenjing Li Mingming Zhao Xiaobin Zhou Zeyao Wang Zhongjie Yu Wenna Liu Wenshu Zhu Haibo Wang Yongjie Wang |
| author_sort | Zhen Sun |
| collection | DOAJ |
| description | Lung cancer is a highly prevalent type of cancer, accounting for 11.6% of all cancer incidences. Early detection and treatment can significantly improve the survival rate and quality of life of patients; however, there is no accurate, effective, and easy-to-use test for early lung cancer screening. In this study, flow cytometry was used to detect the presence of CD45+EpCAM+ cells in tumor tissues and peripheral blood mononuclear cells (PBMCs) in patients with lung cancer. Moreover, the proportion of CD45+EpCAM+ cells in PBMCs of patients with lung cancer was found to be significantly higher than that of healthy volunteers. Tumor-related serum markers level was also measured in the peripheral blood of these patients using an electrochemiluminescence assay. The correlation between CD45+EpCAM+ cells, carcinoembryonic antigen (CEA), and lung cancer was investigated using receiver operating characteristic (ROC) curve analysis, which showed the sensitivity and specificity of the CD45+EpCAM+ cell to be 81.58% and 88.89%, respectively. Further analysis yielded an area under the ROC curve (ROC/area under the curve [AUC]) of 0.845 in patients PBMCs with lung cancer, which was slightly higher than that of CEA (0.732). Therefore, the detection of CD45+EpCAM+ cells in PBMCs may be helpful for the early screening and auxiliary diagnosis of lung cancer. |
| first_indexed | 2024-04-12T05:01:02Z |
| format | Article |
| id | doaj.art-1d8347259cd24abb974c8676952cddcd |
| institution | Directory Open Access Journal |
| issn | 2673-3129 |
| language | English |
| last_indexed | 2024-04-12T05:01:02Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medical Technology |
| spelling | doaj.art-1d8347259cd24abb974c8676952cddcd2022-12-22T03:46:59ZengFrontiers Media S.A.Frontiers in Medical Technology2673-31292022-09-01410.3389/fmedt.2022.982308982308Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancerZhen Sun0Peng Li1Zhaojun Wu2Bin Li3Wenjing Li4Mingming Zhao5Xiaobin Zhou6Zeyao Wang7Zhongjie Yu8Wenna Liu9Wenshu Zhu10Haibo Wang11Yongjie Wang12Qingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, ChinaQingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaQingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaQingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaQingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaDepartment of Epidemiology and Health Statistics, School of Public Health, Qingdao University, Qingdao, ChinaQingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaQingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaQingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaQingdao Sino-Cell Biomed Co., Ltd., Qingdao, ChinaInstitute of Translational Research for Solid Tumor, Qingdao University, Qingdao, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, ChinaLung cancer is a highly prevalent type of cancer, accounting for 11.6% of all cancer incidences. Early detection and treatment can significantly improve the survival rate and quality of life of patients; however, there is no accurate, effective, and easy-to-use test for early lung cancer screening. In this study, flow cytometry was used to detect the presence of CD45+EpCAM+ cells in tumor tissues and peripheral blood mononuclear cells (PBMCs) in patients with lung cancer. Moreover, the proportion of CD45+EpCAM+ cells in PBMCs of patients with lung cancer was found to be significantly higher than that of healthy volunteers. Tumor-related serum markers level was also measured in the peripheral blood of these patients using an electrochemiluminescence assay. The correlation between CD45+EpCAM+ cells, carcinoembryonic antigen (CEA), and lung cancer was investigated using receiver operating characteristic (ROC) curve analysis, which showed the sensitivity and specificity of the CD45+EpCAM+ cell to be 81.58% and 88.89%, respectively. Further analysis yielded an area under the ROC curve (ROC/area under the curve [AUC]) of 0.845 in patients PBMCs with lung cancer, which was slightly higher than that of CEA (0.732). Therefore, the detection of CD45+EpCAM+ cells in PBMCs may be helpful for the early screening and auxiliary diagnosis of lung cancer.https://www.frontiersin.org/articles/10.3389/fmedt.2022.982308/fulllung cancerPBMCsCD45+ EpCAM+ cellsCEAdiagnosis |
| spellingShingle | Zhen Sun Peng Li Zhaojun Wu Bin Li Wenjing Li Mingming Zhao Xiaobin Zhou Zeyao Wang Zhongjie Yu Wenna Liu Wenshu Zhu Haibo Wang Yongjie Wang Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancer Frontiers in Medical Technology lung cancer PBMCs CD45+ EpCAM+ cells CEA diagnosis |
| title | Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancer |
| title_full | Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancer |
| title_fullStr | Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancer |
| title_full_unstemmed | Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancer |
| title_short | Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancer |
| title_sort | circulating cd45 epcam cells as a diagnostic marker for early stage primary lung cancer |
| topic | lung cancer PBMCs CD45+ EpCAM+ cells CEA diagnosis |
| url | https://www.frontiersin.org/articles/10.3389/fmedt.2022.982308/full |
| work_keys_str_mv | AT zhensun circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT pengli circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT zhaojunwu circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT binli circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT wenjingli circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT mingmingzhao circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT xiaobinzhou circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT zeyaowang circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT zhongjieyu circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT wennaliu circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT wenshuzhu circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT haibowang circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer AT yongjiewang circulatingcd45epcamcellsasadiagnosticmarkerforearlystageprimarylungcancer |